Fructooligosaccharides
Also known as: FOS, Oligofructose, Short-chain fructooligosaccharides
This ingredient is classified as unclassified risk (GIRI score: 1.5/10).
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Fructooligosaccharides (FOS) are prebiotic fibres that support beneficial intestinal flora. They are generally well tolerated at low doses. Above 5–10 g/day, bloating, gas, and abdominal discomfort are common. People with irritable bowel syndrome (IBS) or fructose malabsorption may be sensitive to even small amounts.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Prebiotics
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Fructooligosaccharides indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 13:59
Evidence Distribution
-
Observational / other LOW evidence YELLOWGut-kidney axis: Dysbiosis and renal disease. ↗Salvadori M et al.. Gut-kidney axis: Dysbiosis and renal disease.. World J Nephrol. 2026. PMID:41884244.PMID 41884244 ↗Journal World J NephrolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41884244/
-
Observational / other LOW evidence YELLOWBridging the gap of gut microbiome effects of new food additives in food risk assessment: MICODE gut model to test new chitosan… ↗Addazii D et al.. Bridging the gap of gut microbiome effects of new food additives in food risk assessment: MICODE gut model to test new chitosan from seafood waste.. Food Chem. 2026. PMID:41861743.PMID 41861743 ↗Journal Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41861743/
-
Observational / other LOW evidence YELLOWDietary modulation of intestinal integrity and functionality in weaned piglets using short-chain fructooligosaccharides, essential oils and sodium humate. ↗Decundo JM et al.. Dietary modulation of intestinal integrity and functionality in weaned piglets using short-chain fructooligosaccharides, essential oils and sodium humate.. Front Vet Sci. 2026. PMID:41858543.PMID 41858543 ↗Journal Front Vet SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41858543/
-
Observational / other LOW evidence YELLOWEffects of Oligosaccharides in Synergy with Enterococcus hirae F42 Derived from Infant Intestines on the Milk Fermentation Process and Quality. ↗Albadwi F et al.. Effects of Oligosaccharides in Synergy with Enterococcus hirae F42 Derived from Infant Intestines on the Milk Fermentation Process and Quality.. J Dairy Sci. 2026. PMID:41850383.PMID 41850383 ↗Journal J Dairy SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41850383/
-
Observational / other LOW evidence YELLOWApplication of Enzyme Engineering and Synthetic Biology for Modulated Transformation of Fructooligosaccharides (FOSs) to Elucidate the Catalytic Mechanism of Fructofuranosidases. ↗Chen GL et al.. Application of Enzyme Engineering and Synthetic Biology for Modulated Transformation of Fructooligosaccharides (FOSs) to Elucidate the Catalytic Mechanism of Fructofuranosidases.. Foods. 2026. PMID:41829116.PMID 41829116 ↗Journal FoodsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41829116/
-
Observational / other LOW evidence YELLOWEvaluation of an Electronic Nose Coupled with In Vitro Fecal Fermentation as a Screening Tool for Fecal Odor in Cats. ↗Jenjirawatn K et al.. Evaluation of an Electronic Nose Coupled with In Vitro Fecal Fermentation as a Screening Tool for Fecal Odor in Cats.. Animals (Basel). 2026. PMID:41829009.PMID 41829009 ↗Journal Animals (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41829009/
-
Observational / other LOW evidence YELLOWPrebiotics attenuate depressive-like behavior, neuroinflammation and synaptic plasticity in Parkinson's disease by modulating butyrate-producing gut bacteria. ↗de Mendonu00e7a IP et al.. Prebiotics attenuate depressive-like behavior, neuroinflammation and synaptic plasticity in Parkinson's disease by modulating butyrate-producing gut bacteria.. Inflammopharmacology. 2026. PMID:41824184.PMID 41824184 ↗Journal InflammopharmacologyYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41824184/
-
Observational / other LOW evidence YELLOWA Combination of Inulin and Long-Chain Fructooligosaccharides Enhances in Vitro Iron Bioavailability and Supports a Favorable Infant Gut Microbiome. ↗Thomassen GGM et al.. A Combination of Inulin and Long-Chain Fructooligosaccharides Enhances in Vitro Iron Bioavailability and Supports a Favorable Infant Gut Microbiome.. J Agric Food Chem. 2026. PMID:41811133.PMID 41811133 ↗Journal J Agric Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41811133/
-
Observational / other LOW evidence YELLOWA cold-active u03b2-galactosidase from kimchi-derived Latilactobacillus sakei J15: Enzyme properties and probiotic potential. ↗Tan R et al.. A cold-active u03b2-galactosidase from kimchi-derived Latilactobacillus sakei J15: Enzyme properties and probiotic potential.. J AOAC Int. 2026. PMID:41808449.PMID 41808449 ↗Journal J AOAC IntYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41808449/
-
Observational / other LOW evidence YELLOWImmobilization of a Fungal Fructosyltransferase onto Silica Gel and Glutaraldehyde-Functionalized Silica Gel for Biocatalytic Applications. ↗Zanetti Prado JP et al.. Immobilization of a Fungal Fructosyltransferase onto Silica Gel and Glutaraldehyde-Functionalized Silica Gel for Biocatalytic Applications.. ACS Omega. 2026. PMID:41799068.PMID 41799068 ↗Journal ACS OmegaYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41799068/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Fructooligosaccharides. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Fructooligosaccharides
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.